对于不治疗的患者,皮质醇增多症会持续存在甚至加重,5 年生存率仅为 50%。[112]De Tommasi C, Vance ML, Okonkwo DO, et al. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome. J Neurosurg. 2005 Nov;103(5):825-30.http://www.ncbi.nlm.nih.gov/pubmed/16304985?tool=bestpractice.com 导致库欣综合征的症状加重且增加死亡率,死因主要是心血管疾病。通过治疗使皮质醇水平达到正常后,患者的死亡率与一般人群相似。[74]Friedman RB, Oldfield EH, Nieman LK, et al. Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg. 1989 Oct;71(4):520-7.http://www.ncbi.nlm.nih.gov/pubmed/2552045?tool=bestpractice.com死亡率下降:中等质量证据显示,缓解库欣综合征患者的皮质醇增多症可降低死亡率,达到与一般人群接近的水平。[63]Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999 May 18;130(10):821-4.http://www.ncbi.nlm.nih.gov/pubmed/10366371?tool=bestpractice.com受试者<200名的随机对照临床试验(RCT)、受试者>200名且方法学存在缺陷的随机对照临床试验(RCT)、方法学存在缺陷的系统评价或者高质量的观察性(队列)研究。 在有效治疗的第一年内,许多疾病特征(例如面部多血质外貌、紫色条纹和锁骨上脂肪垫)可消退或明显改善。患者体重明显下降,并且糖尿病和高血压的控制改善或消失。皮质醇增多症消退后骨密度稳固升高。尽管大多数患者的并发症得到改善,但一些患者的心血管风险、高血压、肥胖和生活质量的降低即使在生化指标治愈后还可能持续存在。[118]Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003 Jun;88(6):2527-33.http://jcem.endojournals.org/content/88/6/2527.fullhttp://www.ncbi.nlm.nih.gov/pubmed/12788849?tool=bestpractice.com[119]Van der Klaauw AA, Kars M, Biermasz NR, et al. Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf). 2008 Nov;69(5):775-84.http://www.ncbi.nlm.nih.gov/pubmed/18462264?tool=bestpractice.com
垂体腺瘤切除术
结局在很大程度上取决于库欣病患者最初的肿瘤大小。微腺瘤 (大小<1 cm) 的结局良好,65%-90% 的患者可缓解。在这些患者中,5 年复发率为 5% 至 26% ,10 年复发率>10% 至 20%。[64]Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004 Dec;89(12):6348-57.https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2003-032180http://www.ncbi.nlm.nih.gov/pubmed/15579802?tool=bestpractice.com[66]Atkinson AB, Kennedy A, Wiggam MI, et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005 Nov;63(5):549-59.http://www.ncbi.nlm.nih.gov/pubmed/16268808?tool=bestpractice.com[67]Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery. J Clin Endocrinol Metab. 1995 Nov;80(11):3114-20.http://orbi.ulg.ac.be/handle/2268/64110http://www.ncbi.nlm.nih.gov/pubmed/7593411?tool=bestpractice.com[68]Fahlbusch R, Buchfelder M, Muller OA. Transsphenoidal surgery for Cushing's disease. J R Soc Med. 1986 May;79(5):262-9.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1290309/http://www.ncbi.nlm.nih.gov/pubmed/3014145?tool=bestpractice.com[69]Hofmann BM, Fahlbusch R. Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front Horm Res. 2006;34:158-84.http://www.ncbi.nlm.nih.gov/pubmed/16474220?tool=bestpractice.com[70]Knappe UJ, Ludecke DK. Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing's disease. Acta Neurochir Suppl. 1996;65:31-4.http://www.ncbi.nlm.nih.gov/pubmed/8738490?tool=bestpractice.com[71]Stevenaert A, Perrin G, Martin D, et al. Cushing's disease and corticotrophic adenoma: results of pituitary microsurgery. Neurochirurgie. 2002 May;48(2-3 Pt 2):234-65.http://www.ncbi.nlm.nih.gov/pubmed/12058129?tool=bestpractice.com[72]Shimon I, Ram Z, Cohen ZR, et al. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery. 2002 Jul;51(1):57-61;discussion 61-2.http://www.ncbi.nlm.nih.gov/pubmed/12182435?tool=bestpractice.com[73]Sonino N, Zielezny M, Fava GA, et al. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab. 1996 Jul;81(7):2647-52.https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem.81.7.8675592http://www.ncbi.nlm.nih.gov/pubmed/8675592?tool=bestpractice.com[74]Friedman RB, Oldfield EH, Nieman LK, et al. Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg. 1989 Oct;71(4):520-7.http://www.ncbi.nlm.nih.gov/pubmed/2552045?tool=bestpractice.com[75]Patil CG, Veeravagu A, Prevedello DM, et al. Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery. 2008 Aug;63(2):266-70;discussion 270-1.http://www.ncbi.nlm.nih.gov/pubmed/18797356?tool=bestpractice.com 大腺瘤 (大小>1 cm) 患者术后的缓解率<65%,16 个月左右的复发率为 12% 至 45%。[63]Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999 May 18;130(10):821-4.http://www.ncbi.nlm.nih.gov/pubmed/10366371?tool=bestpractice.com[112]De Tommasi C, Vance ML, Okonkwo DO, et al. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome. J Neurosurg. 2005 Nov;103(5):825-30.http://www.ncbi.nlm.nih.gov/pubmed/16304985?tool=bestpractice.com[113]Blevins LS Jr, Christy JH, Khajavi M, et al. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab. 1998 Jan;83(1):63-7.http://jcem.endojournals.org/content/83/1/63.fullhttp://www.ncbi.nlm.nih.gov/pubmed/9435417?tool=bestpractice.com 促甲状腺素、促性腺激素、生长激素、抗利尿激素或皮质类固醇缺乏时,患者需要接受针对性临时或长期治疗。
促肾上腺皮质激素 (ACTH) 依赖性库欣综合征
单侧肾上腺腺瘤的患者行单侧肾上腺切除术后通常可治愈,对侧肾上腺的复发率极低。双侧肾上腺切除术的患者需要监测病情,同时需要皮质类固醇和盐皮质激素的替代治疗。肾上腺癌患者的前景取决于诊断阶段。手术切除之外,其他治疗的利弊仍需探讨且治疗需个体化。
异位 ACTH 的产生
包括一组多样化的群体。分泌 ACTH 的肿瘤性质在很大程度上决定了疾病的结局。许多分泌 ACTH 的肿瘤具有侵袭性且生长迅速。这些情况下,完全切除肿瘤很困难,患者往往死于肿瘤相关并发症。分泌 ACTH 的肿瘤进展缓慢时,肿瘤通常可完全切除,皮质醇增多症和症状可解除。